Drug intelligence / Profile preview

HARRAGAN

Development stage: Preclinical
Lead developer: Harragan

Overview

HARRAGAN is a preclinical-stage therapeutic program being developed by ATVentureCenter for hair regeneration and the treatment of alopecia. Managed under The Crowley Center for Regenerative Biotherapeutics, the program is currently in the early development or preclinical phase. While specific details regarding its modality and molecular mechanism of action have not been publicly disclosed, it is part of a portfolio focused on regenerative biotherapeutics, which includes mesenchymal stem cell (MSC) therapies and exosome-based treatments. HARRAGAN is positioned as a regenerative solution for hair loss disorders.

Brand names: HARRAGAN

Beyond the preview

Go deeper on HARRAGAN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HARRAGAN.

Explore the full profile